Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobeglitazone Add-on to Metformin and Sitagliptin in Type 2 Diabetes
NCT03641352Phase 3Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lobeglitazone in type 2 diabetes mellitus (T2DM), sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03641352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641352.